Novonesis (Novozymes) B (MEX:NSISN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Novonesis (Novozymes) B EBITDA Margin % Related Terms
Novonesis (Novozymes) B EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NSISN vs LIN, SHW, ECL: EBITDA Margin % Comparison
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B (MEX:NSISN) has a EBITDA Margin % of 24.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novonesis (Novozymes) B and its competitors. This is 29% below median its historical median of 34.58. Over the past decade, Novonesis (Novozymes) B's EBITDA Margin % has ranged from 19.27 to 36.12. According to the industry distribution chart, Novonesis (Novozymes) B ranks #319 out of 1584 companies in the Chemicals industry, placing it in the top 20.1%.
Is Novonesis (Novozymes) B's EBITDA Margin % too high?
Novonesis (Novozymes) B's current EBITDA Margin % of 24.42% is 29% below median its 10-year median of 34.58. Over the past 10 years, this metric has ranged from a low of 19.27 to a high of 36.12. The Chemicals industry median EBITDA Margin % is 9.64. Novonesis (Novozymes) B's value of 24.42% is 153.5% above this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #319 out of 1584 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Novonesis (Novozymes) B has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's EBITDA Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #319 out of 1584 companies for EBITDA Margin %. This places Novonesis (Novozymes) B in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 9.64. Novonesis (Novozymes) B's value of 24.42% is 153.5% above this benchmark. Historically, Novonesis (Novozymes) B's own EBITDA Margin % has ranged from 19.27 to 36.12 over the past decade. While the company's 10-year median is 34.58 vs. the industry median of 9.64, Novonesis (Novozymes) B has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.64, based on 1,584 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current EBITDA Margin % of 24.42% is 153.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novonesis (Novozymes) B and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current EBITDA Margin % is 24.42%, which is 29% below median its own 10-year median of 34.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Novonesis (Novozymes) B (MEX:NSISN) has a current EBITDA Margin % of 24.42%. The stock's GF Value™ is MXN979.45, compared to a current price of MXN911.11 — trading 7% below its estimated fair value. The current EBITDA Margin % is 24.42%, which is 29% below median its 10-year median of 34.58 and 153.5% above the Chemicals industry median of 9.64. Novonesis (Novozymes) B's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Novonesis (Novozymes) B (MEX:NSISN), the current EBITDA Margin % is 24.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (MEX:NSISN) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be undervalued.
The current stock price of MXN911.11 is trading 7% below its estimated GF Value™ of MXN979.45.
Key valuation signals for MEX:NSISN:
EBITDA Margin %: 24.42% (29% below median its 10-year median of 34.58)
GF Value™: MXN979.45 vs. price of MXN911.11 (7% below fair value)
Industry Position: 153.5% above the Chemicals median (#319 of 1584)
No single metric tells the full story. See the MEX:NSISN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
91GF Score
Get the complete analysis for MEX:NSISN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NSISN has been successfully added to your 
